Dr. Youjia Li, the Director of Research and Development at Leman Biotech, was invited to participate in the prestigious 2023 Guangzhou Cell Therapy Summit held on February 15-16. During the conference, Dr. Li delivered a keynote speech and engaged in insightful discussions with fellow experts on the development, challenges, and solutions in the field of immune cell therapy.
(1)(1).png)
Tumor immunotherapy has made remarkable progress in recent years, significantly extending the survival period for some cancer patients. However, several challenges remain. The overall response rate and durability of curative effects in the treatment of hematological tumors need improvement, while immune cell therapy for solid tumors has yet to demonstrate satisfactory results. To address these obstacles, Dr. Li emphasized the importance of collaboration and concentrated efforts from various stakeholders to achieve long-term control and eventual cure of tumors.
Leman Biotech has developed a groundbreaking technology called Meta 10 to overcome the bottle neck of T cell exhaustion in the tumor microenvironment. Dr. Li presented detailed experimental data to showcase the unique capabilities of Meta 10 in significantly improving the response rate and curative effects of existing immunotherapies. The molecular mechanism behind Meta 10 involves promoting metabolic reprogramming of terminally exhausted T cells through a pyruvate-MPC-dependent approach. This leads to enhanced oxidative phosphorylation metabolism, improved proliferation capacity, sustained killing function, and increased memory efficiency, ultimately enabling long-term tumor control and potential cure.
Additionally, Dr. Li provided updates on Leman Biotech's research and development progress in three pipelines, highlighting the initiation of IIT clinical research for their first cell therapy product. The presentation also shed light on Leman Biotech's business model for new drug research and development and technology authorization, emphasizing the company's commitment to advancing collaboration and achieving mutual success in the pursuit of curing tumors.
Dr. Li's participation in the 2023 Guangzhou Cell Therapy Summit and the insightful exchange of ideas exemplify Leman Biotech's dedication to advancing the field of immune cell therapy and realizing the vision of curing tumors.
